These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 18535620)

  • 1. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.
    Yaacov B; Eliahoo E; Lazar I; Ben-Shlomo M; Greenbaum I; Panet A; Zakay-Rones Z
    Cancer Gene Ther; 2008 Dec; 15(12):795-807. PubMed ID: 18535620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus.
    Vigil A; Park MS; Martinez O; Chua MA; Xiao S; Cros JF; Martínez-Sobrido L; Woo SL; García-Sastre A
    Cancer Res; 2007 Sep; 67(17):8285-92. PubMed ID: 17804743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
    Fournier P; Bian H; Szeberényi J; Schirrmacher V
    Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein.
    Bian H; Wilden H; Fournier P; Peeters B; Schirrmacher V
    Int J Oncol; 2006 Dec; 29(6):1359-69. PubMed ID: 17088973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
    Li H; Dutuor A; Fu X; Zhang X
    J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus.
    Puhlmann J; Puehler F; Mumberg D; Boukamp P; Beier R
    Oncogene; 2010 Apr; 29(15):2205-16. PubMed ID: 20101224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
    Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
    J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
    Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
    Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin.
    Lazar I; Yaacov B; Shiloach T; Eliahoo E; Kadouri L; Lotem M; Perlman R; Zakay-Rones Z; Panet A; Ben-Yehuda D
    J Virol; 2010 Jan; 84(1):639-46. PubMed ID: 19864394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme.
    Freeman AI; Zakay-Rones Z; Gomori JM; Linetsky E; Rasooly L; Greenbaum E; Rozenman-Yair S; Panet A; Libson E; Irving CS; Galun E; Siegal T
    Mol Ther; 2006 Jan; 13(1):221-8. PubMed ID: 16257582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptin enhances the oncolytic properties of Newcastle disease virus.
    Wu Y; Zhang X; Wang X; Wang L; Hu S; Liu X; Meng S
    Intervirology; 2012; 55(4):276-86. PubMed ID: 21865658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application.
    Apostolidis L; Schirrmacher V; Fournier P
    Int J Oncol; 2007 Nov; 31(5):1009-19. PubMed ID: 17912426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress in using Newcastle disease virus for tumor therapy: a review].
    Wu Y; Hao J; Li D
    Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.
    Janke M; Peeters B; de Leeuw O; Moorman R; Arnold A; Fournier P; Schirrmacher V
    Gene Ther; 2007 Dec; 14(23):1639-49. PubMed ID: 17914407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
    Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
    J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newcastle disease virus: a promising agent for tumour immunotherapy.
    Zhao L; Liu H
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
    Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
    Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity.
    Fournier P; Arnold A; Wilden H; Schirrmacher V
    Int J Oncol; 2012 Mar; 40(3):840-50. PubMed ID: 22102168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newcastle disease virus as an oncolytic agent.
    Ravindra PV; Tiwari AK; Sharma B; Chauhan RS
    Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiling in PC12 cells infected with an oncolytic Newcastle disease virus strain.
    Balogh A; Bátor J; Markó L; Németh M; Pap M; Sétáló G; Müller DN; Csatary LK; Szeberényi J
    Virus Res; 2014 Jun; 185():10-22. PubMed ID: 24637408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.